ea0094p31 | Bone and Calcium | SFEBES2023
Tang Jonathan
, Fraser William
, Phillips Jonathan
, Piec Isabelle
, Dunn Rachel
, Keerie Catriona
, Lewis Steff
, Ralston Stuart
, Investigators ZiPP
Zoledronate in the Prevention of Pagets disease (ZiPP) trial (ClinicalTrials.gov ID:NCT03859895) is a multi-centre, double-blind, placebo-controlled, randomised trial of Zoledronic acid (ZA) in sequestosome1 (SQSTM1) mutation carriers. SQSTM1 mutation has high penetrance and is associated with the early onset of Pagets disease of bone. Participants with the SQSTM1 genotype received either a single dose of IV 5mg ZA (Aclasta, Novartis); intervention group n...